Alere to Market VitaPath Genetics' Spina Bifida Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Alere has licensed the worldwide marketing rights to VitaPath Genetics' spina bifida risk assessment assay, the companies announced Wednesday.

The deal also gives Alere the right to develop with Foster City, Calif.-based VitaPath additional product line extensions mainly focusing on fetal health.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.